Background HF therapy was intensified over time, with increased prescription of mineralocorticoid receptor antagonists (21% vs. 52%; <i>p</i> = 0.039) and β-blockers (67% vs. 91%). This evidence concerns the gene NR3C2 and hydrops fetalis.